
Two large Pharma companies must face antitrust suit over generic delays. Merck and Glenmark Pharmaceuticals are headed for an antitrust trial over claims they used an illegal patent settlement to delay generic versions of cholesterol reducer Zetia, reported Bloomberg.
Read more: Merck To Buy Blood Cancer Biotech Imago For $1.35B
Judge Rebecca Beach Smith denied summary judgment to the drugmakers, which have spent years fighting allegations that Merck dropped a patent infringement case against Glenmark and paid it to keep its generic Zetia on the shelves longer.
Drug purchasers filed their original suit in 2018 and amended the case the following year. The plaintiffs allege Merck paid Glenmark around $800 million in an “unlawful reverse-payment” to delay the launch of its Zetia copycat—which was the first generic to hit the market back in Dec. 2016—for nearly five years.
Merck and Glenmark attempted to escape the lawsuit by filing for a court judgment in August 2020.
Featured News
Court Order Temporarily Halts U.S. Consumer Financial Protection Bureau Layoffs
Feb 16, 2025 by
CPI
Nokia Poised to Gain EU Approval for $2.3 Billion Infinera Acquisition
Feb 16, 2025 by
CPI
Turkey Fines Frito-Lay in Antitrust Crackdown
Feb 16, 2025 by
CPI
Advances Bill to Strengthen Antitrust Enforcement Through AI
Feb 16, 2025 by
CPI
Intel Faces Potential Breakup as Broadcom and TSMC Explore Deals
Feb 16, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon